Healthcare Industry News:  CytoCore 

Biopharmaceuticals Drug Delivery Licensing

 News Release - March 1, 2006

CytoCore Announces Licensing the First Drug Delivery System That Therapeutically Addresses Cervical Cancer Lesions

CHICAGO, IL--(Healthcare Sales & Marketing Network)--Mar 1, 2006 -- Ewire -- CytoCore, Inc. (OTC BB:MCDG.OB ) today announced that it has licensed from University Hospitals of Cleveland a new Drug Delivery System (DDS) developed by physician George Gorodeski, M.D., Ph.D., that will for the first time give the physicians the ability to apply FDA approved drugs to existing cervical lesions.

The DDS is comprised of an applicator handle and drug-delivery modality in the form of a patch that provides a timed-release delivery of the therapeutic agent directly to the surface of the cervix. The handle is a further development of CytoCore's e2 Collector handle, which has been specifically designed to quickly, safely and accurately position and deposit the patch on the cervix.

Current Pap screening programs often find the presence of cervical dysplasia or lesions in early stages. The present treatment options are either surgical removal of the lesion, or repeated follow-ups with Pap testing. While only a fraction of cervical dysplasia cases progress to invasive cervical cancer, the atmosphere of medical uncertainty on a finding of dysplasia, and the limited treatment options (surgery or wait) place an unnecessary burden on the physicians and their patients, and could explain, in part, the rising number of cervical surgeries, some of which may be unnecessary.

Abnormally growing cervical cells, including dysplastic cells, can be treated with different types of anti-viral or other inhibiting medications to control their growth. Early attempts at applying such drugs to cervical lesions typically led to unacceptable toxic effects to the surrounding tissues, so the practice was abandoned. The new DDS will, for the first time, offer the physician a therapeutic treatment option for cervical lesions. This new device will allow for a drug or combination(s) of FDA approved drugs to be applied directly and specifically to the cervix. CytoCore believes that the nature of the device patent filed will allow for the drug manufacturer to file for a new use patent on the drugs used with the patch.


Source: CytoCore

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.